Evaluation l’ivermectine comme prophylaxie et pour le traitement.

L’invermectine a un profil de sécurité établi pour l’utilisation humaine et est approuvée à la fois par la FDA américaine et par Santé Canada.

NEW: Early Treatment, NEW: Featured, NEW: Français, NEW: Integrative Therapy, NEW: Prevention & Treatment
COVID, COVID-19, L'ivermectine, podcast, Prophylaxie, traitement

Interview with Dr. Pelech regarding COVID-19 issues

Dr. Stephen Pelech provides an end of year review of the science that supports or refutes the public health policies imposed during the COVID-19 crisis.

Deanna McLeod Pt. 3: Big Pharma and Vaccine Conflict of Interest

Deanna McLeod’s interview on Open Mike with Mr. Michael Thiessen, on the topic of conflicts of interests surrounding the COVID-19 injections.

The Blind Spot in COVID-19 Vaccination Policies: Under Reported Adverse Events

In this peer-reviewed publication, Dr Patrick Provost examines the post-vaccination adverse events reporting system and the inherent weaknesses that may result in underreporting. Based on

Evaluation l’ivermectine comme prophylaxie et pour le traitement.

Evaluation l’ivermectine comme prophylaxie et pour le traitement.

Related Posts

Deanna McLeod Pt. 3: Big Pharma and Vaccine Conflict of Interest

Canadian Covid Care Alliance